Key result
Transcatheter aortic valve replacement has demonstrated non-inferiority to surgical aortic valve replacement in intermediate and low-risk patients with severe aortic stenosis, though challenges remain regarding long-term durability and bicuspid valves.
Why the study?
Although non-inferiority has been demonstrated in intermediate and low-risk patients, several challenges need to be addressed before expanding TAVR to younger patients.
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with severe aortic stenosis at intermediate to low surgical risk?
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with severe aortic stenosis at intermediate to low surgical risk?
TAVR is a safe and effective alternative to SAVR in intermediate and low-risk patients, though long-term durability and management of specific anatomical challenges like bicuspid valves require further study.
Answers are grounded in this paper and cite their sources.
Supports TAVR in intermediate/low-risk severe AS; leaves open durability and bicuspid questions before younger-patient expansion.
TAVR has become the standard treatment in patients at increased surgical risk (STS or EuroSCORE II ≥4% or logistic EuroSCORE I ≥ 10% or other risk factors not included in these scores such as frailty, porcelain aorta, sequelae of chest radiation) and it is increasingly being performed in patients at intermediate to low (STS or EuroSCORE II <4% or logistic EuroSCORE I < 10%) surgical risk. Although non-inferiority has been demonstrated in intermediate and low-risk patients, several challenges need to be addressed before expansion to younger patients. Current trends, trials results, and remaining challenges are summarized and discussed in this review.
No takes yet. Share an insight, caveat, or question.
Ielasi et al. (2019) conducted a review in Severe symptomatic aortic valve stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve replacement has demonstrated non-inferiority to surgical aortic valve replacement in intermediate and low-risk patients with severe aortic stenosis, though challenges remain regarding long-term durability and bicuspid valves.
Synapse has enriched 10 related papers. Consider them for comparative context: